Sept. 10, 2012 – A recent settlement between Johnson & Johnson/Janssen and multiple states to resolve claims that the company promoted unapproved uses for its antipsychotic drugs Risperdal and Invega is significant not only because J&J will pay $181 million but also because, among several provisions, the settlement restricts J&J’s ability to distribute reprints of […]
Read more